BRAID
Research type
Research Study
Full title
Breast Screening; Risk Adaptive Imaging for Density
IRAS ID
251317
Contact name
Fiona Gilbert
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Clinicaltrials.gov Identifier
Duration of Study in the UK
4 years, 7 months, 6 days
Research summary
BRAID is a randomised, multi-centre study assessing the impact of supplementary imaging in the detection of breast cancer in women participating in the UK national breast screening programme who have dense breast parenchyma.
Breast density, a measure of the amount of fibro-glandular tissue, is one of the strongest knows risk factors for breast cancer, the 10% of women with extremely dense breasts are at a 4-fold increased breast cancer risk compared to women with ‘fatty’ breasts and high breast density is associated with reduced sensitivity of mammography meaning that women with dense breasts have an increased probability of developing an interval cancer (cancer being detected between screening rounds) and of cancer being detected at a later stage.
This trial aims to answer a timely question about how best to screen women with dense breasts for breast cancer. Breast cancer screening reduces breast cancer specific mortality by 20%, however only 53% of the cancers being detected are small (<15mm).The current national breast screening programme (NHS BSP) offers all women aged 50-70 screening with 3-yearly mammograms. It aims to reduce breast cancer mortality by detecting small cancers thereby reducing the number of late stage diagnoses.
BRAID will randomise women whose recent screening mammogram shows that they have dense breasts to either standard of care (no supplementary imaging) or supplementary imaging with abbreviated MRI (ABB-MRI), automated whole breast ultrasound (ABUS) or contrast enhanced spectral mammography (CESM). All of these imaging techniques have been shows to be more sensitive at detecting cancers within fibro-glandular tissue and our hypothesis is that more cancers will be detected at an earlier stage with the addition of supplemental imaging.
REC name
London - Surrey Research Ethics Committee
REC reference
19/LO/0350
Date of REC Opinion
8 May 2019
REC opinion
Further Information Favourable Opinion